Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
525.2 USD | +3.19% | +4.63% | +11.37% |
Financials (USD)
Sales 2024 * | 171B | Sales 2025 * | 182B | Capitalization | 122B |
---|---|---|---|---|---|
Net income 2024 * | 7.98B | Net income 2025 * | 9.04B | EV / Sales 2024 * | 0.81 x |
Net Debt 2024 * | 17.19B | Net Debt 2025 * | 12.73B | EV / Sales 2025 * | 0.74 x |
P/E ratio 2024 * |
15.4
x | P/E ratio 2025 * |
13.4
x | Employees | 104,900 |
Yield 2024 * |
1.18% | Yield 2025 * |
1.27% | Free-Float | 99.55% |
Latest transcript on Elevance Health, Inc.
1 day | +3.19% | ||
1 week | +4.63% | ||
Current month | +1.28% | ||
1 month | +2.72% | ||
3 months | +11.90% | ||
6 months | +11.91% | ||
Current year | +11.37% |
Managers | Title | Age | Since |
---|---|---|---|
Gail Boudreaux
CEO | Chief Executive Officer | 63 | 17-11-19 |
Mark Kaye
DFI | Director of Finance/CFO | 45 | 23-09-05 |
Ratnakar Lavu
CTO | Chief Tech/Sci/R&D Officer | 53 | Feb. 04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 74 | 13-09-30 | |
Director/Board Member | 55 | 22-10-31 | |
Gail Boudreaux
CEO | Chief Executive Officer | 63 | 17-11-19 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.22% | 18 M€ | +1.40% | - | |
2.36% | 1,026 M€ | +6.11% | - | |
2.07% | 8 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-18 | 525.2 | +3.19% | 2,595,100 |
24-04-17 | 509 | +0.39% | 1,401,591 |
24-04-16 | 507 | +1.38% | 1,127,280 |
24-04-15 | 500.1 | +0.52% | 1,031,789 |
24-04-12 | 497.5 | -0.89% | 1,188,685 |
Delayed Quote Nyse, April 18, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.37% | 122B | |
+16.47% | 98.93B | |
-29.05% | 39.16B | |
-0.62% | 39.45B | |
-0.10% | 21.15B | |
-14.25% | 3.06B | |
-40.53% | 964M | |
-33.71% | 313M |
- Stock Market
- Equities
- ELV Stock